German health economists say the costs associated with both typical and drug-resistant forms of tuberculosis throughout Europe already total more than $7 billion annually in lost productivity, as well as around $677 million in direct treatment costs. The lead author of the study, published in the European Respiratory Journal, called drug-resistant TB a "time bomb" and urged governments and drugmakers to invest in research to combat the disease.

Full Story:

Related Summaries